Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer

NCT06225011 | Recruiting Phase 1 DMC FDA Drug

• 2 other identifiers: 23-001744NCI-2023-09939
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

This phase I trial tests whether fluoxetine (prozac) works to modify the tumor immune cells before surgery in patients with colorectal cancer. Fluoxetine is a commonly used selective serotonin reuptake inhibitor (SSRI) prescribed for major depressive disorder and generalized anxiety. Giving fluoxetine may modify the immune cell composition in the tumor and its microenvironment and may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread in patients with colorectal cancer.

Conditions

Colorectal Adenocarcinoma

Outcome Measures

Primary Outcomes (1)

• Immune cell composition and microenvironment

  Will be assessed by changes in the immune cell composition in the tumor and its microenvironment before and after exposure to selective serotonin reuptake inhibitors therapy. Fixed tumor samples will be analyzed by immunohistochemistry for immune cell tumor infiltration and relevant lineage/activation/exhaustion markers. Will use descriptive statistics and graphical displays to compare the changes in tumor immune markers between the pre- and post-treatment tissue.

  within a year of surgery

Study Arms (1)

Treatment (fluoxetine)

EXPERIMENTAL

Patients receive fluoxetine PO once QD for 10 days prior to surgery.

Drug: Fluoxetine

Interventions

Fluoxetine DRUG

Receive PO

Treatment (fluoxetine)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female ≥ 18 years of age at visit 1
• Previously untreated cytologically or histologically confirmed colorectal adenocarcinoma that will not need neoadjuvant therapy
• Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study
• World Health Organization (WHO) Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• Absolute neutrophil count (ANC) ≥ 1.5x10\^9/L
• Platelets ≥ 100x10\^9/L
• Hemoglobin ≥ 9 g/dL
• Serum creatinine (sCr) ≤ 1.5 x upper limit of normal (ULN)
• Creatinine clearance (Ccr) ≥ 40 mL/min (as calculated by Modified Cockcroft-Gault formula)
• Serum total bilirubin ≤ 1.5 x ULN
• Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase \[SGOT\]) / alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase \[SGPT\]) ≤ 2.5 x ULN
• Baseline corrected QT (QTc) within normal limits per the Bazett formula. Any electrocardiogram (EKG) done prior to consent is acceptable for baseline QTc monitoring.
• Normal QTc ranges from 350-450 ms for adult men and from 360-460 ms for adult women

You may not qualify if:

• Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the participant or the quality of the data
• A diagnosis of metastatic colorectal adenocarcinoma
• Individuals who have received neoadjuvant chemotherapy prior to the planned colon cancer resection
• Individuals with absolute or relative contraindications to fluoxetine
• Baseline prolonged QTc
• Concurrently taking tamoxifen, pimozide, or thioridazine
• Individuals using other SSRIs, serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), lithium or other antidepressants at time of initial biopsy
• Currently active second primary malignancy or history of malignancy less than 5 years prior to the time of study eligibility (Patients with history of skin cancers excluding melanoma will be eligible for participation)

Sponsors & Collaborators

• Jonsson Comprehensive Cancer Center: lead

Study Sites (1)

UCLA / Jonsson Comprehensive Cancer Center

Los Angeles, California, 90095, United States

RECRUITING

MeSH Terms

Interventions

Fluoxetine

Intervention Hierarchy (Ancestors)

Propylamines; Amines; Organic Chemicals

Study Officials

• Jasmine Mitchell, MD

  UCLA / Jonsson Comprehensive Cancer Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jasmine Mitchell, MD

CONTACT

310-825-0712; jlmitchell@mednet.ucla.edu

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 4, 2024
• First Posted: January 25, 2024
• Study Start: March 20, 2025
• Primary Completion (Estimated): July 1, 2026
• Study Completion (Estimated): July 1, 2027
• Last Updated: May 11, 2026

Record last verified: 2026-05

Locations

US (1)